PUNE, India, August 31, 2017 /PRNewswire/ --
According to a new market research report "Allergy Diagnostics Market by Products (Assay Kits, Immunoassay & Elisa Analyzers, Luminometers, Services), Allergens (Food, Inhaled, Drug), Tests (In Vivo, In Vitro), End Users (Hospital, Diagnostic Laboratory) - Global Forecast to 2022", published by MarketsandMarkets™, the market is expected to reach USD 5.74 Billion by 2022 from USD 3.49 Billion in 2017, at a CAGR of 10.5% from 2017 to 2022.
Browse 105 Market Data Tables and 32 Figures spread through 149 Pages and in-depth TOC on "Allergy Diagnostics Market"
Early buyers will receive 10% customization on this report
The high incidence of allergic diseases is one of the major factors driving the growth of this market. The rising environmental pollution levels and the growing need for relatively faster, accurate, and high-throughput technologies for allergy diagnostics are the major factors supporting the growth of this market.
Assay kits are estimated to dominate the market in 2017
On the basis of product & service, the allergy diagnostic market is segmented into assay kits, instruments, and services. The instruments segment is further sub segmented into immunoassay analyzers, luminometers, ELISA analyzers, and other instruments. The assay kits segment is expected to dominate the global Allergy Diagnostics Market in 2017. Efficient performance, reliability, and great level of precision are key drivers increasing the demand for assay kits.
Download PDF Brochure: http://www.marketsandmarkets.com/pdfdownload.asp?id=232871701
Inhaled allergens are estimated to command the largest market share in 2017
On the basis of allergens, the Allergy Diagnostics Market is segmented into inhaled allergens, food allergens, drug allergens, and other allergens. In 2017, the inhaled allergens segment is expected to account for the largest share of the Allergy Diagnostics Market. Increasing environmental pollution is one of the major factors driving the growth of this segment.
North America estimated to account for the major market share in 2017
Based on region, the Allergy Diagnostics Market is segmented into North America, Europe, Asia, and the Rest of the World (RoW). In 2017, North America is expected to command the largest share of the Allergy Diagnostics Market. The large share of this segment can primarily be attributed to the increasing healthcare expenditure, coverage of allergy diagnostics tests in medical insurance, and the strong presence of players in this region.
Talk To Our Research Analysts: http://www.marketsandmarkets.com/speaktoanalyst.asp?id=232871701
Key players in the Allergy Diagnostics Market include Thermo Fisher Scientific Inc. (US), Siemens AG (Germany), Danaher Corporation (US), Omega Diagnostics Group PLC (UK), Hitachi Chemical Co., Ltd. (Japan), bioMérieux SA (France), Stallergenes Greer (UK), HOB Biotech Group Suzhou Co., Ltd. (China), HYCOR Biomedical (US), Lincoln Diagnostics, Inc. (US), EUROIMMUN AG (Germany), INDOOR Biotechnologies, Inc. (US), DR. FOOKE - Achterrath Laboratorien GmbH (Germany), R-Biopharm AG (Germany), GA Generic Assays GmbH (Germany), Tecan Trading AG (Switzerland), DST Diagnostische Systeme & Technologien GmbH (Germany), ROXALL Medical GmbH (Germany), ALK-Abelló A/S (Denmark), Astra Biotech GmbH (Germany), HAL Allergy Group (Netherlands), Theradiag (France), and Demeditec Diagnostics GmbH (Germany).
Browse Related Reports:
Immunoassay Market by Product & Service (Reagents & Kits, Analyzers, Software, Services), Technique (ELISA, Rapid Test), Application (Infectious Diseases, Endocrinology, Oncology), End User (Clinical Labs, Hospitals) - Global Forecast to 2021
Antinuclear Antibody Test Market by Product (Reagents & Assay Kits, Systems, Software, Services), Technique (Immunofluorescence, Elisa, Multiplex), Disease (Rheumatoid Arthritis, SLE), End User (Clinical Labs, Hospitals) - Forecast to 2021
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 5000 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model - GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets's flagship competitive intelligence and market research platform, "RT" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
701 Pike Street
Suite 2175, Seattle,
WA 98101, United States
Connect with us on LinkedIn @ http://www.linkedin.com/company/marketsandmarkets